Tiziana Life Sciences to begin patient dosing in Phase 2 Alzheimer's trial next week

Tiziana Life Sciences (NASDAQ: TLSA) has begun enrolling patients in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, in early Alzheimer’s disease and expects to dose the first patient next week; the study will test foralumab as monotherapy and in combination with approved anti-amyloid drugs lecanemab or donanemab. The program is supported by TSPO‑PET imaging from a lecanemab-treated patient showing persistent microglial activation despite amyloid clearance, bolstering Tiziana’s hypothesis that residual neuroinflammation can be targeted by foralumab-induced regulatory T cells; baseline cognitive testing, fluid biomarkers and TSPO‑PET scans have been completed for initial participants. The trial’s primary goals are safety, tolerability and efficacy with key endpoints including TSPO‑PET measures of neuroinflammation, cognitive outcomes and amyloid/tau biomarkers, aiming to determine whether reducing microglial activation alone or in combination with anti-amyloid therapy can slow cognitive decline.

Analysis

Tiziana Life Sciences (NASDAQ: TLSA) has begun enrollment in a randomized, placebo‑controlled Phase 2 trial of intranasal foralumab in early Alzheimer’s disease and expects to dose the first patient next week. The study will evaluate foralumab as monotherapy and in combination with FDA‑approved anti‑amyloid agents lecanemab (Leqembi) or donanemab, and baseline cognitive testing, fluid biomarkers and TSPO‑PET imaging have been completed for the first screened participants.

The company highlights TSPO‑PET imaging from a lecanemab‑treated patient showing persistent microglial activation despite amyloid plaque reduction, which Tiziana and SAB chair Dr. Howard Weiner cite as biological rationale for targeting residual neuroinflammation. Tiziana frames foralumab’s mechanism—induction of regulatory T cells that migrate to the brain and calm activated microglia—as supported by prior reductions in microglial activation in secondary progressive multiple sclerosis, increasing mechanistic plausibility for an anti‑inflammatory approach in AD.

The Phase 2 endpoints focus on safety, tolerability and efficacy with key readouts of TSPO‑PET neuroinflammation, cognitive outcomes, and amyloid/tau biomarkers to test whether microglial reduction slows cognitive decline or adds benefit to anti‑amyloid therapy. Market signals are mildly positive (sentiment score 0.35), reflecting constructive sentiment on a novel mechanism but acknowledging early‑stage, binary trial risk and added interpretive complexity from combination arms and multi‑modal biomarkers.

Key Decisions for Investors

• Consider establishing a small, speculative position ahead of initial dosing and early biomarker readouts given mechanistic plausibility and mild positive sentiment, but cap exposure because Phase 2 efficacy remains unproven
• Monitor enrollment milestones, TSPO‑PET changes and the timing/definitions of cognitive endpoints closely—meaningful reductions in microglial activation or early cognitive signal would be clear upside catalysts while null or ambiguous biomarker results would be materially negative
• Avoid large, concentrated stakes until controlled efficacy data are reported and consider hedging or using options to manage the binary outcome risk posed by the combination arm and complex biomarker endpoints